[JAZZ] Jazz Pharmaceuticals plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 8.62 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 110.4 Change: 3.79 (3.56%)
Ext. hours: Change: 0 (0%)

chart JAZZ

Refresh chart

Strongest Trends Summary For JAZZ

JAZZ is in the medium-term down -31% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding60.49 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 6.21% Sales Growth - Q/Q-5.74% P/E
P/E To EPS Growth P/S6.97 P/BV6.6 Price/Cash Per Share
Price/Free Cash Flow23.32 ROA6.85% ROE16.99% ROI8.26%
Current Ratio5 Quick Ratio4.86 Long Term Debt/Equity1.51 Debt Ratio0.17
Gross Margin90.71% Operating Margin30.68% Net Profit Margin17.95% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-3.26 M Cash From Operating Activities18.29 M Gross Profit281.01 M
Net Profit96.56 M Operating Profit116.76 M Total Assets3.24 B Total Current Assets1.1 B
Total Current Liabilities220.58 M Total Debt1.33 B Total Liabilities1.93 B Total Revenue309.3 M
Technical Data
High 52 week183.18 Low 52 week115.94 Last close128.44 Last change0.6%
RSI25.6 Average true range3.64 Beta1.32 Volume518.32 K
Simple moving average 20 days-7.38% Simple moving average 50 days-4.27% Simple moving average 200 days-14.11%
Performance Data
Performance Week-8.13% Performance Month-3.84% Performance Quart0.82% Performance Half-18.65%
Performance Year-18.73% Performance Year-to-date3.61% Volatility daily1.89% Volatility weekly4.23%
Volatility monthly8.66% Volatility yearly30% Relative Volume302.29% Average Volume652.73 K
New High New Low

News

2019-04-18 20:05:05 | Are Hedge Funds Right About Jazz Pharmaceuticals?

2019-04-16 09:30:01 | JAZZ vs. ZTS: Which Stock Is the Better Value Option?

2019-04-16 08:47:07 | Should We Be Cautious About Jazz Pharmaceuticals plc's NASDAQ:JAZZ ROE Of 16%?

2019-04-16 08:45:12 | 3 Reasons Why Jazz JAZZ Is a Great Growth Stock

2019-04-11 09:46:01 | Concert Pharma Initiates Early-Stage Schizophrenia Study

2019-04-09 10:46:50 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

2019-04-04 18:20:12 | Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

2019-04-04 18:16:58 | Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe

2019-04-04 10:34:00 | Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations

2019-04-01 05:00:00 | Stocks That Would Have Made You Rich Today

2019-03-28 09:30:01 | Jazz JAZZ Down 0.4% Since Last Earnings Report: Can It Rebound?

2019-03-27 16:30:08 | Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

2019-03-27 07:52:54 | The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

2019-03-26 16:13:00 | Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

2019-03-26 15:33:36 | What Should Investors Know About The Future Of Jazz Pharmaceuticals plc’s NASDAQ:JAZZ?

2019-03-26 08:22:41 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

2019-03-25 09:19:13 | Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

2019-03-22 15:01:06 | Analysts Reduce Jazz Pharmaceuticals’ Target Price in March

2019-03-21 07:51:16 | The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

2019-03-20 21:05:34 | FDA approves Jazz Pharmaceutical sleep disorder drug

2019-03-20 20:02:29 | Jazz Pharma's sleep disorder treatment gets FDA nod

2019-03-20 18:53:00 | Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

2019-03-20 11:14:03 | Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

2019-03-20 08:00:00 | Here are the biggest analyst calls of the day: Lyft, Monster, FedEx, Rockwell Automation & more

2019-03-19 11:09:22 | FDA decision on Jazz Pharmaceuticals narcolepsy drug expected Wednesday

2019-03-12 09:56:01 | Is Jazz Pharmaceuticals JAZZ a Good Value Investor Pick?

2019-03-12 07:00:11 | The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom

2019-03-11 09:19:01 | The Best And Worst Stocks of the 10-Year Bull Market

2019-03-07 14:22:20 | The 10 Best and 10 Worst Stocks of This 10-Year Bull Market

2019-03-05 16:05:00 | Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference

2019-03-05 07:15:00 | 3 Best Biotech Bargain Stocks on the Market Right Now

2019-02-28 11:24:41 | Should You Take Comfort From Insider Transactions At Jazz Pharmaceuticals plc NASDAQ:JAZZ?

2019-02-28 09:15:02 | Too Much Talking, Not Enough Action

2019-02-28 08:43:01 | Jazz Pharmaceuticals JAZZ Surges: Stock Moves 7.9% Higher

2019-02-27 08:13:48 | The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

2019-02-27 07:13:12 | Jazz Pharma JAZZ Q4 Earnings & Sales Beat, Stock Up 8%

2019-02-27 03:03:18 | Edited Transcript of JAZZ earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-27 02:08:02 | Jazz Pharmaceuticals PLC JAZZ Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:31:00 | Jazz Pharma stock jumps 9% as biotech tops Wall Street Q4 views

2019-02-26 16:05:00 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results

2019-02-26 14:30:00 | Jazz Pharmaceuticals Plc to Host Earnings Call

2019-02-24 14:30:00 | 2 Stocks You Really Should Consider Shorting This Week

2019-02-20 15:09:08 | Mylan MYL to Report Q4 Earnings: What's in the Offing?

2019-02-15 08:10:00 | New Research: Key Drivers of Growth for IPG Photonics, Keane Group, Jazz Pharmaceuticals, Tredegar, Carriage Services, and Surgery Partners — Factors of Influence, Major Initiatives and Sustained Production

2019-02-14 16:05:00 | Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors

2019-02-12 16:05:00 | Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019

2019-02-12 09:53:02 | Factors to Know Ahead of Herbalife's HLF Q4 Earnings

2019-02-06 10:10:03 | Why Jazz JAZZ Could Beat Earnings Estimates Again

2019-01-30 10:54:08 | What Investors Should Know About Jazz Pharmaceuticals plc’s NASDAQ:JAZZ Financial Strength

2019-01-29 08:03:20 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.